Entering text into the input field will update the search result below

PTC Therapeutics poised for $20M milestone from licensee Roche on advancement of mid-stage study of RG7916 in spinal muscular atrophy; shares ahead 4% premarket

Oct. 21, 2016 9:08 AM ETPTC Therapeutics, Inc. (PTCT) StockBy: Douglas W. House, SA News Editor6 Comments
  • Micro cap PTC Therapeutics (NASDAQ:PTCT) is up 4% premarket on light volume in response to its announcement that Roche (OTCQX:RHHBY) has initiated a Phase 2 clinical trial, SUNFISH, assessing RG7916 in pediatric and adult patients with Type 2/3 spinal muscular atrophy (SMA).
  • The first part of the study will evaluate the safety and tolerability of escalating doses of RG7916 in ~36 subjects. After the optimal dose is selected, the study will move into a pivotal second stage to assess efficacy for up to 24 months followed by an open-label extension. The transition will trigger a $20M milestone to PTC from Roche.
  • A trial in Type 1 SMA patients, FIREFISH, should commence in the coming months.
  • SMA is an inherited disorder caused a deficiency in a protein called SMN which is coded by a gene called SMN1. A similar gene, SMN2, can code for SMN as well, but not as productively. RG7916 and RG7800 (an earlier SMA candidate) modify the splicing of the SMN2 gene to generate more SMN.
  • Previously: PTC Therapeutics up 17% on licensee Roche's move into mid-stage study in spinal muscular dystrophy (Sept. 30)

Recommended For You

About PTCT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PTCT--
PTC Therapeutics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.